OMER
Omeros Corporation NASDAQ Listed Oct 8, 2009$14.64
Mkt Cap $1.1B
52w Low $2.95
79.5% of range
52w High $17.65
50d MA $12.09
200d MA $9.01
P/E (TTM)
-285.8x
EV/EBITDA
-10.8x
P/B
—
Debt/Equity
-2.0x
ROE
2.8%
P/FCF
-9.4x
RSI (14)
—
ATR (14)
—
Beta
2.53
50d MA
$12.09
200d MA
$9.01
Avg Volume
1.1M
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
The Omeros Building · Seattle, WA 98119 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.55 | 3.14 | +670.9% | 10.56 | +7.2% | +14.4% | +3.2% | +3.1% | +4.0% | +9.0% | — |
| Nov 13, 2025 | AMC | -0.58 | -0.19 | +67.2% | 6.28 | +5.7% | +25.3% | +44.6% | +35.4% | +30.9% | +31.1% | — |
| Aug 14, 2025 | AMC | -0.55 | -0.53 | +3.6% | 4.12 | +2.7% | +7.0% | +2.4% | +5.8% | +1.7% | +8.7% | — |
| May 15, 2025 | AMC | -0.57 | -0.65 | -14.0% | 3.95 | -1.3% | -18.5% | -15.9% | -16.7% | -21.3% | -18.5% | — |
| Mar 31, 2025 | AMC | -0.78 | -0.63 | +19.2% | 8.22 | +11.4% | -3.8% | -2.6% | -10.5% | -14.1% | -16.1% | — |
| Nov 13, 2024 | AMC | -0.70 | -0.64 | +8.6% | 4.19 | +5.5% | +65.9% | +61.1% | +41.3% | +43.9% | +43.9% | — |
| Aug 7, 2024 | AMC | -1.14 | -1.12 | +1.8% | 4.15 | -0.5% | -5.8% | -0.7% | +3.1% | -0.5% | -1.0% | — |
| May 15, 2024 | AMC | -0.58 | -0.74 | -27.6% | 4.17 | -24.9% | -20.6% | -17.3% | -20.9% | -19.4% | -18.0% | — |
| Apr 1, 2024 | AMC | -0.56 | -0.63 | -12.5% | 3.19 | -8.5% | -4.4% | -1.3% | -2.2% | +7.5% | +7.2% | — |
| Nov 9, 2023 | AMC | -0.62 | -0.82 | -32.3% | 1.26 | -4.8% | -0.8% | +11.1% | +18.3% | +19.8% | +19.8% | — |
| Aug 9, 2023 | AMC | -0.60 | -0.70 | -16.7% | 4.33 | -0.7% | -3.0% | -0.7% | -7.9% | -13.9% | -18.2% | — |
| May 9, 2023 | AMC | -0.55 | -0.63 | -14.5% | 5.00 | +4.0% | +21.2% | +9.4% | +14.2% | +7.8% | +6.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $13.47 | $13.40 | -0.5% | -1.6% | -0.7% | +0.4% | +0.4% | +9.4% |
| Jan 27 | D. Boral Capital | Maintains | Buy → Buy | — | $11.53 | $11.53 | +0.0% | +9.9% | +2.4% | +3.6% | +1.4% | +1.6% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.09 | $14.52 | +3.1% | -4.5% | -11.4% | -9.0% | -10.4% | -7.2% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $14.09 | $14.52 | +3.1% | -4.5% | -11.4% | -9.0% | -10.4% | -7.2% |
| Dec 24 | D. Boral Capital | Maintains | Buy → Buy | — | $8.75 | $16.44 | +87.9% | +75.5% | +79.5% | +89.4% | +93.8% | +96.3% |
| Dec 1 | D. Boral Capital | Maintains | Buy → Buy | — | $9.69 | $9.83 | +1.4% | -0.1% | -2.7% | +9.6% | +13.8% | +12.0% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $6.28 | $6.64 | +5.7% | +25.3% | +44.6% | +35.4% | +30.9% | +31.1% |
| Oct 16 | D. Boral Capital | Maintains | Buy → Buy | — | $10.42 | $9.15 | -12.2% | -5.7% | -22.2% | -20.8% | -24.5% | -25.7% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | +139.8% | +97.8% | +101.2% | +92.0% |
| Oct 15 | WBB Securities | Maintains | Strong Buy → Strong Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | +139.8% | +97.8% | +101.2% | +92.0% |
| Oct 15 | Needham | Maintains | Hold → Hold | — | $4.10 | $11.59 | +182.7% | +154.1% | +139.8% | +97.8% | +101.2% | +92.0% |
| Oct 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.10 | $11.59 | +182.7% | +154.1% | +139.8% | +97.8% | +101.2% | +92.0% |
| Sep 3 | D. Boral Capital | Maintains | Buy → Buy | — | $4.29 | $4.24 | -1.2% | -2.6% | -2.6% | -2.8% | -1.9% | -0.7% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.12 | $4.23 | +2.7% | +7.0% | +2.4% | +5.8% | +1.7% | +8.7% |
| Aug 15 | Needham | Maintains | Hold → Hold | — | $4.12 | $4.23 | +2.7% | +7.0% | +2.4% | +5.8% | +1.7% | +8.7% |
| Jul 25 | D. Boral Capital | Maintains | Buy → Buy | — | $3.59 | $3.86 | +7.5% | +6.7% | +15.6% | +10.6% | +7.2% | +7.8% |
| Jun 30 | D. Boral Capital | Maintains | Buy → Buy | — | $3.20 | $3.20 | +0.0% | -6.2% | -7.2% | -3.4% | +0.0% | -3.8% |
| May 16 | Needham | Maintains | Hold → Hold | — | $3.95 | $3.90 | -1.3% | -18.5% | -15.9% | -16.7% | -21.3% | -18.5% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $3.80 | $4.22 | +11.1% | +16.6% | +3.4% | +3.9% | -15.3% | -12.6% |
| May 7 | D. Boral Capital | Maintains | Buy → Buy | — | $6.34 | $6.33 | -0.2% | +0.2% | -0.5% | -2.5% | -40.1% | -30.1% |
| Apr 11 | D. Boral Capital | Maintains | Buy → Buy | — | $5.86 | $5.87 | +0.2% | +14.8% | +19.3% | +17.2% | +15.4% | +15.7% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $8.22 | $9.16 | +11.4% | -3.8% | -2.6% | -10.5% | -14.1% | -16.1% |
| Apr 1 | Needham | Maintains | Hold → Hold | — | $8.22 | $9.16 | +11.4% | -3.8% | -2.6% | -10.5% | -14.1% | -16.1% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $9.10 | $8.97 | -1.4% | +0.0% | -0.9% | +0.7% | -6.4% | -2.0% |
| Feb 20 | D. Boral Capital | Maintains | Buy → Buy | — | $9.25 | $9.54 | +3.1% | +3.9% | -0.8% | -6.2% | -8.6% | -5.4% |
| Jan 17 | Needham | Maintains | Hold → Hold | — | $9.18 | $9.18 | +0.0% | +1.6% | -0.3% | +1.2% | -1.9% | -8.8% |
| Jan 16 | D. Boral Capital | Maintains | Buy → Buy | — | $8.90 | $9.11 | +2.4% | +3.1% | +4.8% | +2.8% | +4.4% | +1.2% |
| Dec 19 | Needham | Maintains | Hold → Hold | — | $7.46 | $9.71 | +30.2% | +37.3% | +38.2% | +35.5% | +34.0% | +40.2% |
| Nov 10 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $1.26 | $1.20 | -4.8% | -0.8% | +11.1% | +18.3% | +19.8% | +19.8% |
| Dec 8 | UBS | Downgrade | Buy → Neutral | — | $2.22 | $2.10 | -5.4% | -0.9% | -7.2% | -4.1% | +1.4% | -10.8% |
| Nov 8 | BofA Securities | Downgrade | Neutral → Underperform | — | $3.28 | $3.34 | +1.8% | -2.4% | -14.0% | -18.9% | -16.5% | -13.1% |
| Jun 8 | BofA Securities | Downgrade | Buy → Neutral | — | $2.42 | $2.30 | -5.0% | -9.9% | -11.6% | -13.6% | -16.5% | -19.4% |
| Oct 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.67 | $5.82 | +2.6% | +9.7% | +12.9% | +13.9% | +14.5% | +11.5% |
| Oct 8 | JP Morgan | Downgrade | Neutral → Underweight | — | $7.43 | $7.09 | -4.6% | -9.8% | -3.6% | -4.2% | -0.7% | +4.0% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.08 | $6.99 | -1.3% | +1.8% | +4.9% | -5.4% | +1.1% | +0.6% |
| Oct 4 | Maxim Group | Downgrade | Buy → Hold | — | $8.54 | $8.08 | -5.4% | -14.8% | -17.1% | -15.6% | -13.0% | -21.5% |
| Jun 18 | WBB Securities | Maintains | Strong Buy → Strong Buy | — | $14.97 | $15.19 | +1.5% | +0.6% | +2.3% | +3.3% | +3.2% | +3.8% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.65 | $18.65 | +0.0% | -2.7% | -3.2% | -3.5% | -4.0% | -5.3% |
| Feb 1 | UBS | Maintains | Buy → Buy | — | $19.46 | $19.88 | +2.2% | +5.1% | +8.2% | +11.4% | +11.3% | +8.6% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.46 | $19.87 | +2.1% | -2.4% | -4.3% | +1.1% | +0.2% | -1.2% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.29 | $14.30 | +0.1% | +1.6% | +1.6% | +5.3% | +10.6% | +12.0% |
| Oct 20 | BofA Securities | Maintains | Buy → Buy | — | $11.08 | $11.71 | +5.7% | +1.6% | +0.6% | -0.3% | -3.8% | -7.8% |
| Sep 1 | Wedbush | Maintains | Neutral → Neutral | — | $11.95 | $11.86 | -0.8% | -9.3% | -11.6% | -13.6% | -16.3% | -11.3% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.95 | $12.85 | -0.8% | -3.9% | -6.9% | -9.0% | -7.3% | -9.6% |
| Dec 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $14.80 | $14.59 | -1.4% | -2.4% | -2.9% | +3.0% | -10.1% | -11.1% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.62 | $19.46 | -0.8% | -0.1% | -8.9% | -6.3% | -5.4% | -1.5% |
| Aug 10 | Maxim Group | Maintains | Buy → Buy | — | $21.70 | $22.28 | +2.7% | -18.3% | -11.6% | -5.0% | -7.2% | -5.4% |
| May 17 | Wedbush | Maintains | Neutral → Neutral | — | $20.01 | $19.90 | -0.5% | +1.2% | +0.5% | +3.9% | +3.9% | -1.1% |
| Mar 23 | Maxim Group | Maintains | Buy → Buy | — | $15.75 | $14.75 | -6.3% | -10.5% | -22.0% | -22.3% | -24.4% | -29.1% |
| Mar 23 | Wedbush | Downgrade | Outperform → Neutral | — | $15.75 | $14.75 | -6.3% | -10.5% | -22.0% | -22.3% | -24.4% | -29.1% |
No insider trades available.
8-K · 8.01
!! High
Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Eli Lilly acquired Kyverna Therapeutics for an undisclosed amount, expanding its immunology portfolio with Kyverna's cell therapy candidates.
May 4
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K
Unknown — 8-K Filing
Omeros reported full-year 2025 financial results, signaling operational updates investors should monitor for revenue trends, profitability, and pipeline progress affecting future growth prospects.
Mar 31
Data updated apr 26, 2026 5:22pm
· Source: massive.com